Cutera, Inc. (NASDAQ:CUTR) – Equities research analysts at Gabelli issued their FY2022 earnings per share (EPS) estimates for Cutera in a research report issued to clients and investors on Friday. Gabelli analyst J. Tsai forecasts that the medical device company will post earnings per share of $2.30 for the year. Gabelli currently has a “Buy” rating on the stock.
CUTR has been the topic of several other reports. Zacks Investment Research lowered shares of Cutera from a “hold” rating to a “sell” rating in a report on Monday, January 1st. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. Finally, Maxim Group reissued a “hold” rating on shares of Cutera in a report on Wednesday, November 8th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $37.33.
Cutera (CUTR) traded down $2.10 during mid-day trading on Monday, reaching $48.40. 243,200 shares of the company’s stock traded hands, compared to its average volume of 184,343. Cutera has a 52-week low of $18.50 and a 52-week high of $52.90. The company has a market cap of $670.58, a price-to-earnings ratio of 23.61, a P/E/G ratio of 1.44 and a beta of 0.41.
Cutera (NASDAQ:CUTR) last released its earnings results on Wednesday, February 14th. The medical device company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.33 by $0.09. Cutera had a net margin of 19.80% and a return on equity of 18.31%. The firm had revenue of $47.60 million for the quarter, compared to analyst estimates of $43.96 million. During the same period last year, the firm earned $0.30 EPS. The business’s quarterly revenue was up 25.6% compared to the same quarter last year.
In related news, insider James A. Reinstein sold 7,175 shares of Cutera stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $45.35, for a total transaction of $325,386.25. Following the sale, the insider now directly owns 132,284 shares in the company, valued at approximately $5,999,079.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $47.40, for a total transaction of $47,400.00. Following the sale, the director now owns 8,259 shares in the company, valued at $391,476.60. The disclosure for this sale can be found here. Insiders have sold a total of 24,018 shares of company stock worth $1,104,766 over the last ninety days. 3.30% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of CUTR. BlackRock Inc. boosted its position in Cutera by 33.2% during the 4th quarter. BlackRock Inc. now owns 2,015,640 shares of the medical device company’s stock worth $91,409,000 after buying an additional 502,933 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Cutera in the 2nd quarter worth approximately $3,175,000. Cortina Asset Management LLC acquired a new position in shares of Cutera in the 4th quarter worth approximately $4,789,000. Guggenheim Capital LLC acquired a new position in shares of Cutera in the 4th quarter worth approximately $3,777,000. Finally, Bogle Investment Management L P DE lifted its position in shares of Cutera by 77.2% in the 4th quarter. Bogle Investment Management L P DE now owns 185,174 shares of the medical device company’s stock worth $8,397,000 after purchasing an additional 80,700 shares during the period. Institutional investors and hedge funds own 93.03% of the company’s stock.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.